In some people, new-onset depression may stem from the same buildup of toxic plaques in the brain that have long been linked ...
A new study found that Alzheimer's medications called cholinesterase inhibitors may help slow down cognitive decline in ...
LIFT-AD trial did not meet primary endpoint of GST and key secondary endpoints of cognition (ADAS-Cog11) and function ...
In a study recently published in Alzheimer's & Dementia, researchers at Karolinska Institutet and Shandong Provincial ...
A recent study has revealed that maintaining a diet rich in choline throughout life could be a key to preventing (AD).
Athira Pharma's trial of fosgonimeton for Alzheimer's disease patients failed to meet its primary endpoint. Bothell, Wash., biopharmaceutical company said Tuesday that neither the trial's primary ...
Sept. 21. Dealing with Alzheimer’s disease goes beyond a diagnosis; it’s a journey that profoundly affects not only those directly impacted but also their loved ones who support them along the way.
Athira Pharma (ATHA) stock cratered post-market after the company said a Phase 2/3 study of its drug Alzheimer’s drug ...
Shares of Athira Pharma tumbled after the company's trial of fosgonimeton for Alzheimer's disease patients failed to meet its primary endpoint. Shares plummeted 74% to 74 cents in after-hours trading ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results